论文部分内容阅读
目的探讨格列吡嗪治疗对２型糖尿病病人血清胰岛素样生长因子（ＩＧＦ）及其结合蛋白（ＩＧＦＢＰ）的影响。方法采用病例对照及治疗前后自身对照研究，了解糖尿病病人空腹血清ＩＧＦ－１、ＩＧＦ－２和ＩＧＦＢＰ－１、ＩＧＦＢＰ－３水平及格列吡嗪治疗２周后的改变情况。其中糖尿病组４０例，正常对照组９０例，两组年龄无显著性差异，Ｐ＞０．０５。结果与正常对照组比，糖尿病组治疗前ＩＧＦ－１水平降低（２３４．４１±１４１．７８ｖｓ １８１．７６±１０４．４８ｎｇ／ｍｌＰ＜０．０５），ＩＧＦＢＰ－１水平升高（４７． ６５±３１． ７８ｖｓ ６８． ８２±４３． １８ｎｇ／ｍｌ， Ｐ＜０． ０１），ＩＧＦ－２和 ＩＧＦＢＰ－３改变不明显。格列吡嗪治疗后 ＩＧＦ－Ｉ升高（１８１． ８±１０４．５ ｖｓ ２０９．０±８８．２ ｎｇ／ｍｌ，Ｐ＜０．０５）；ＩＧＦＢＰ－１则明显下降（６８．８２±４３．１８ ｖｓ ４３．７２±３４． ３５ ｎｇ／ｍｌ，ｐ＝０．００１）；ＩＧＦ－Ⅱ，ＩＧＦＢＰ－３无明显变化。结论格列吡嗪治疗可改善２型糖尿病所导致的血清ＩＧＦ－Ｉ和ＩＧＦＢＰ－１水平改变。
Objective To investigate the effects of glipizide on serum insulin-like growth factor (IGF) and its binding protein (IGFBP) in type 2 diabetic patients. Methods A case-control study and self-control study before and after treatment were conducted to investigate the changes of fasting serum IGF-1, IGF-2, IGFBP-1 and IGFBP-3 in diabetic patients and the changes of glipizide two weeks later. There were 40 cases in diabetic group and 90 cases in normal control group, there was no significant difference between the two groups (P> 0.05). Results Compared with the normal control group, the levels of IGF-1 in diabetes mellitus before treatment were lower (234.41 ± 141.78 vs 181.76 ± 104.48ng / ml, P <0.05) and IGFBP-1 31. 78 vs 68. 82 ± 43. 18ng / ml, P <0.01), IGF-2 and IGFBP-3 change was not obvious. Glipizide treatment increased IGF-I (181. 8 ± 104.5 vs 209.0 ± 88.2 ng / ml, P <0.05), while IGFBP-1 decreased significantly (68.82 ± 43 .18 vs 43.72 ± 34.35 ng / ml, p = 0.001). There was no significant change in IGF-Ⅱand IGFBP-3. Conclusion Glipizide treatment can improve the changes of serum IGF-I and IGFBP-1 levels caused by type 2 diabetes mellitus.